SCHEMBL14646191

SCHEMBL14646191

O=C(O)Cn1c(-c2ccc(-c3nc4ccccc4n3CC(=O)O)cc2)nc2ccccc21

nearest known ligand 0.94

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.94
▸ KDM4E B2RXH2 3/20 0.94
▸ LMNA P02545 1/20 0.64
▸ TSHR P16473 1/20 0.64
▸ APEX1 P27695 1/20 0.61
▸ ALDH1A1 P00352 4/20 0.58
▸ PDE6D O43924 1/20 0.58
▸ ALDH2 P05091 1/20 0.58
▸ ALDH3A1 P30838 1/20 0.58
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ PTGDR2 Q9Y5Y4 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ HIF1A Q16665 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15643888 0.97 HSD17B10 (1.00) HSD17B10KDM4ELMNATSHRAPEX1
SCHEMBL28141462 0.89 KDM4E (0.75) HSD17B10KDM4ELMNATSHRALDH1A1
SCHEMBL28140776 0.88 KDM4E (0.73) HSD17B10KDM4ELMNATSHRALDH1A1
SCHEMBL14397087 0.84 KDM4E (0.78) HSD17B10KDM4ELMNATSHRALDH1A1
SCHEMBL14646187 0.83 KDM4E (0.71) HSD17B10KDM4EAPEX1ALDH1A1MEN1
SCHEMBL7393259 0.82 KDM4E (0.64) HSD17B10KDM4ELMNAAPEX1ALDH1A1
SCHEMBL3587930 0.82 KDM4E (0.69) HSD17B10KDM4ELMNATSHRAPEX1
SCHEMBL14646220 0.82 KDM4E (0.69) HSD17B10KDM4EAPEX1ALDH1A1MEN1
SCHEMBL22769595 0.82 HSD17B10 (0.74) HSD17B10KDM4ELMNATSHRALDH1A1
SCHEMBL28815849 0.82 HSD17B10 (0.74) HSD17B10KDM4ELMNATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 — — US disclosed
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 — — US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 — — US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 — — US disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 — — WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY PRNP, TBCA, HSPA5 HSD17B10 1758/4885KDM4E 4549/4885LMNA 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback